You are here

Zylo Therapeutics Inc.

Company Information
Address
105A BEN HAMBY DR
GREENVILLE, SC 29615-5701
United States


http://www.zylotherapeutics.com

Information

UEI: RR11WNA1RBB3

# of Employees: 5


Ownership Information

HUBZone Owned: No

Socially and Economically Disadvantaged: No

Woman Owned: No



Award Charts




Award Listing

  1. Development of an endocannabinoid microparticle formulation for the topical treatment of cutaneous manifestations of lupus erythematosus.

    Amount: $147,861.00

    Project Summary/Abstract Approximately 500,000 people in the U.S. suffer from cutaneous lupus lesions (CLE), with a significant impact on quality of life.4 Yet, there is no cure, the treatment options ...

    STTRPhase I2023Department of Health and Human Services National Institutes of Health
  2. Development and optimization of a nitric oxide releasing microparticle-basedtopical treatment for onychomycosis

    Amount: $600,000.00

    Onychomycosis is an extremely common and difficult-to-treat fungal nail infection that causes nail disfigurement, pain, associated infections, and psychosocial effects that negatively impact quality o ...

    STTRPhase I2022Department of Health and Human Services National Institutes of Health
  3. Optimization of a nanoparticle-based topical PDE5i formulation for treatment of erectile dysfunction

    Amount: $263,446.00

    Abstract It is increasingly recognized that erectile dysfunction (ED) not only affects a man’s sex life but also impacts his relationships and overall psychological well-being. An indication of the ...

    STTRPhase I2022Department of Health and Human Services National Institutes of Health
  4. Development of microparticle-based topical treatments for treating erectile dysfunction in patients refractory to oral PDE5 inhibitors

    Amount: $1,705,226.00

    Abstract Following radical prostatectomy (RP), virtually all men experience erectile dysfunction (ED), primarily due to damage to the cavernous nerve (CN). Yet, first-line treatments for ED, orally ad ...

    SBIRPhase II2021Department of Health and Human Services National Institutes of Health
  5. Optimization of microparticle-based topical treatments for treating erectile dysfunction in patients refractory to oral PDE5 inhibitors

    Amount: $225,000.00

    Radical prostatectomyRPis a commonly used treatment option for localized prostate cancerUnfortunatelythe procedure carries a risk of post surgical complications including a high risk of erectile dysfu ...

    STTRPhase I2019Department of Health and Human Services National Institutes of Health
US Flag An Official Website of the United States Government